Opinion|Videos|November 27, 2024

Navigating Healthcare Access and Decision-Making

Key Takeaways

  • Integrating HER2-directed therapies into NSCLC treatment requires alignment with existing protocols and timely updates to decision-making processes.
  • Establishing frameworks for rapid incorporation of emerging therapies and fostering adaptive decision-making processes are essential strategies.
SHOW MORE

An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.

Video content above is prompted by the following:

  • What are the key challenges in integrating HER2-directed therapies into existing internal decision-making processes for NSCLC?
  • What strategies can be employed to ensure timely updates to internal decision-making processes as new HER2-directed therapies emerge?
  • How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo